Publicacións nas que colabora con MARÍA JOSÉ FAUS DADER (31)

2019

  1. Clinical pharmacy services: From cost-effectiveness analysis to a productivity indicators model

    European Journal of Hospital Pharmacy

  2. Pharmacogenetics of platinum-based chemotherapy: impact of DNA repair and folate metabolism gene polymorphisms on prognosis of non-small cell lung cancer patients

    Pharmacogenomics Journal, Vol. 19, Núm. 2, pp. 164-177

2018

  1. Impact of DNA repair, folate and glutathione gene polymorphisms on risk of non small cell lung cancer

    Pathology Research and Practice, Vol. 214, Núm. 1, pp. 44-52

2017

  1. Contribution of genetic factors to platinum-based chemotherapy sensitivity and prognosis of non-small cell lung cancer

    Mutation Research - Reviews in Mutation Research, Vol. 771, pp. 32-58

  2. Cytokine single-nucleotide polymorphisms and risk of non-small-cell lung cancer

    Pharmacogenetics and Genomics, Vol. 27, Núm. 12, pp. 438-444

  3. Interleukins as new prognostic genetic biomarkers in non-small cell lung cancer

    Surgical Oncology, Vol. 26, Núm. 3, pp. 278-285

2016

  1. Liquid biopsy in early stage lung cancer

    Translational Lung Cancer Research, Vol. 5, Núm. 5, pp. 517-524

  2. Pharmacogenetic predictors of toxicity to platinum based chemotherapy in non-small cell lung cancer patients

    Pharmacological Research, Vol. 111, pp. 877-884

  3. Resultados negativos asociados a la medicación en los pacientes con fibrilación auricular permanente atendidos en un servicio de urgencias hospitalario

    Emergencias, Vol. 28, Núm. 2, pp. 75-82

2015

  1. MET/HGF targeted drugs as potential therapeutic strategies in non-small cell lung cancer

    Pharmacological Research, Vol. 102, pp. 90-106

  2. MET: A new promising biomarker in non-small-cell lung carcinoma

    Pharmacogenomics, Vol. 16, Núm. 6, pp. 631-647

  3. Negative outcomes associated with medication in patients with chronic atrial fibrillation who present at the emergency department

    Journal of Clinical Pharmacy and Therapeutics, Vol. 40, Núm. 4, pp. 452-460

  4. PTEN and PI3K/AKT in non-small-cell lung cancer

    Pharmacogenomics, Vol. 16, Núm. 16, pp. 1843-1862

2012

  1. Efecto del seguimiento farmacoterapéutico en pacientes con hiperparatiroidismo secundario tratados con cinacalcet

    Farmacia Hospitalaria, Vol. 36, Núm. 5, pp. 321-327

  2. Pharmacogenetic polymorphisms contributing to toxicity induced by methotrexate in the southern Spanish population with rheumatoid arthritis

    OMICS A Journal of Integrative Biology, Vol. 16, Núm. 11, pp. 589-595

2011

  1. Role of the hospital pharmacy and therapeutics committee in detecting and regulating off-label drug use

    International Journal of Clinical Pharmacy

2010

  1. Adecuación de la prescripción al alta hospitalaria en pacientes con enfermedad pulmonar obstructiva crónica

    Farmacia Hospitalaria, Vol. 34, Núm. 4, pp. 188-193

  2. Factores de riesgo en una población anciana: escalas de valoración para la prevención de fracturas de cadera

    Revista Espanola de Cirugia Ortopedica y Traumatologia, Vol. 54, Núm. 3, pp. 167-173

  3. Pharmacogenetics of osteoporosis-related bone fractures: Moving towards the harmonization and validation of polymorphism diagnostic tools

    Pharmacogenomics, Vol. 11, Núm. 9, pp. 1287-1303

  4. Reacciones adversas al tratamiento quimioterápico en pacientes con cancer de pulmón

    Atencion Farmaceutica, Vol. 12, Núm. 2, pp. 79-88